Preclinical anticancer activity of DNA-based cleavage molecules.
Deoxyribozymes (DNAzymes) are DNA residue-based molecules capable of specific cleavage of complementary mRNA. As such, they are more stable counterparts for the earlier discovered ribozymes. A handful of studies have shown the potential of DNAzymes against cancer both in cell culture and importantly in vivo models. This relatively new molecular entity may progress to clinical trials provided that more extensive testing is carried out at the preclinical stage. While a significant amount of work has gone into chemically stabilizing the molecule, delivery is one area that needs particular attention.
Dass
Crispin R
CR
Department of Orthopaedics, St. Vincents Hospital, 35 Victoria Parade, Fitzroy, 3065, Australia. cris_dass@yahoo.com.au
D000818:Animals; D002478:Cells, Cultured; D021881:DNA, Catalytic / Q000494:pharmacology* / Q000627:therapeutic use; D004277:DNA, Single-Stranded / Q000494:pharmacology / Q000627:therapeutic use; D016758:Genes, jun; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D009955:Ornithine Decarboxylase / Q000235:genetics; D051879:Twist-Related Protein 1 / Q000235:genetics; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics
C400152:DNA enzyme ED5; D021881:DNA, Catalytic; D004277:DNA, Single-Stranded; D051879:Twist-Related Protein 1; D040301:Vascular Endothelial Growth Factor Receptor-2; D009955:Ornithine Decarboxylase